Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects

British Journal of Pharmacology

Volumn 173, Issue 10, 2016, Pages 1580-1588

  Boyce, M ^a   Warrington, S ^a   Cortezi, B ^a   Zollner S ^b   Vauleon S ^b   Swinkels, D W ^c   Summo, L ^b   Schwoebel, F ^b   Riecke, K ^b  

^a Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

^b NOXXON PHARMA AG   (Germany)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; HEPCIDIN; IRON; LEXAPTEPID PEGOL; PLACEBO; TRANSFERRIN; NOX-H94; OLIGORIBONUCLEOTIDE;

ADULT; AGED; ANEMIA; ANEMIA OF CHRONIC DISEASE; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; DYSHIDROSIS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; INJECTION SITE BLEEDING; INJECTION SITE REACTION; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OROPHARYNX PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG MONITORING; STRUCTURE ACTIVITY RELATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HEALTHY VOLUNTEERS; HEPCIDINS; HUMANS; IRON; MALE; OLIGORIBONUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFERRIN;

EID: 84962685102     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13433     Document Type: Article

References (32)

1. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al., (2015). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110-6202.
2. EMA (2007). Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/28307: European Medicines Agency.
3. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, et al., (2010). Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116: 1574-1584.
4. de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, et al., (2016). Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica 101: 38-45.
5. Fung E, Nemeth E, (2013). Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 98: 1667-1676.
6. Ganz T, (2003). Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783-788.
7. Georgiev P, Lazaroiu M, Ocroteala L, Grudeva-Popova J, Gheorghita E, Vasilica M, et al., (2014). Abstract 3847: the anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: a phase II pilot study. Cancer Res 74: 3847.
8. Hörl WH, (2007). Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 22: 480-489.
9. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T, (2014). Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46: 678-684.
10. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al., (2000). LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480: 147-150.
11. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al., (2010). Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 56: 1570-1579.
12. MacDougall IC, Cooper AC, (2002). Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 (Suppl 11): 39-43.
13. Moebius U, Feuerer W, Fenzl E, van Swelm R, Swinkels DW, Hohlbaum A, (2015) Abstract 536: a phase I study investigating the safety, tolerability, pharmacokinetics and pharmacodynamic activity of the hepcidin antagonist PRS-080#022. Results from a randomized, placebo controlled, double-blind study following single administration to healthy subjects. 57th ASH Annual Meeting & Exposition Dec 5-8, 2015.
14. Nemeth E, Ganz T, (2006). Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26: 323-342.
15. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al., (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093.
16. Park CH, Valore EV, Waring AJ, Ganz T, (2001). Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806-7810.
17. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
18. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al., (2001). A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276: 7811-7819.
19. Preza GC, Pinon R, Ganz T, Nemeth E, (2013). Cellular catabolism of the iron-regulatory peptide hormone hepcidin. PLoS One 8: e58934.
20. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al., (2012). Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125: 991-999.e991.
21. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC, (2007). Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109: 4038-4044.
22. Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, et al., (2013). The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 121: 2311-2315.
23. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K, (2010). Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116: 3627-3634.
24. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, et al., (2008). Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 3 e2706.
25. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al., (2009). Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114: 181-186.
26. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al., (2007). High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13: 1096-1101.
27. van Eijk LT, John AS, Schwoebel F, Summo L, Vauleon S, Zollner S, et al., (2014). Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124: 2643-2646.
28. Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Tiu RV, et al,. (2015). Abstract 537: Phase 1 study of a hepcidin antagonist, LY2787106, in cancer-associated anemia. 57th ASH Annual Meeting & Exposition Dec 5-8, 2015.
29. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV, (2010). Serum ferritin: past, present and future. Biochim Biophys Acta 1800: 760-769.
30. Weiss G, Goodnough LT, (2005). Anemia of chronic disease. N Engl J Med 352: 1011-1023.
31. Witcher DR, Leung D, Hill KA, de Rosa DC, Xu J, Manetta J, et al., (2013). LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys. Blood 122: 3433.
32. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, et al., (2010). Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 12: 646-657.